ATE350037T1 - Methode zur behandlung des tourette-syndroms - Google Patents
Methode zur behandlung des tourette-syndromsInfo
- Publication number
- ATE350037T1 ATE350037T1 AT98307170T AT98307170T ATE350037T1 AT E350037 T1 ATE350037 T1 AT E350037T1 AT 98307170 T AT98307170 T AT 98307170T AT 98307170 T AT98307170 T AT 98307170T AT E350037 T1 ATE350037 T1 AT E350037T1
- Authority
- AT
- Austria
- Prior art keywords
- syndrome
- treating tourette
- tourette
- treating
- disorder
- Prior art date
Links
- 208000000323 Tourette Syndrome Diseases 0.000 title abstract 2
- 208000016620 Tourette disease Diseases 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000023655 Tic Diseases 0.000 abstract 1
- 208000021703 chronic tic disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000016686 tic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Saccharide Compounds (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Photoreceptors In Electrophotography (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5798797P | 1997-09-05 | 1997-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE350037T1 true ATE350037T1 (de) | 2007-01-15 |
Family
ID=22013937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98307170T ATE350037T1 (de) | 1997-09-05 | 1998-09-04 | Methode zur behandlung des tourette-syndroms |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6127373A (de) |
| EP (1) | EP0901789B1 (de) |
| JP (1) | JP3004969B2 (de) |
| KR (1) | KR100621249B1 (de) |
| AT (1) | ATE350037T1 (de) |
| AU (1) | AU732157B2 (de) |
| CA (1) | CA2246584C (de) |
| CY (1) | CY1106402T1 (de) |
| DE (1) | DE69836783T2 (de) |
| DK (1) | DK0901789T3 (de) |
| ES (1) | ES2278405T3 (de) |
| IL (1) | IL125951A (de) |
| MY (1) | MY122052A (de) |
| NZ (1) | NZ331742A (de) |
| PT (1) | PT901789E (de) |
| TW (1) | TW448048B (de) |
| ZA (1) | ZA988102B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| EA200500342A1 (ru) * | 2002-09-17 | 2005-08-25 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Гетероциклические замещённые пиперазины для лечения шизофрении |
| CA2498215A1 (en) * | 2002-10-28 | 2004-05-06 | Warner-Lambert Company Llc | Oxindole substituted piperazine derivatives |
| BRPI0410419A (pt) * | 2003-05-16 | 2006-05-30 | Pfizer Prod Inc | tratamento para a ansiedade com ziprasidona |
| KR20060009938A (ko) * | 2003-05-16 | 2006-02-01 | 화이자 프로덕츠 인코포레이티드 | 양극성 장애 및 연관된 증상의 치료 |
| EP1626722A1 (de) * | 2003-05-16 | 2006-02-22 | Pfizer Products Inc. | Ziprasidon zur verbesserung der wahrnehmung |
| CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| JP2007502856A (ja) * | 2003-05-16 | 2007-02-15 | ファイザー・プロダクツ・インク | 精神病性障害および抑うつ性障害の治療 |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| MA41169A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| US12637461B2 (en) | 2022-10-18 | 2026-05-26 | Pfizer Inc. | Compounds for the activation of AMPK |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| DE3923045A1 (de) * | 1989-07-13 | 1991-01-17 | Merck Patent Gmbh | Indolderivate |
| US5314885A (en) * | 1992-09-11 | 1994-05-24 | Mcneilab, Inc. | Cyclic benzylamino, benzylamido, and benzylimido antipsychotic agents |
-
1998
- 1998-08-27 IL IL12595198A patent/IL125951A/xx not_active IP Right Cessation
- 1998-09-02 TW TW087114577A patent/TW448048B/zh not_active IP Right Cessation
- 1998-09-03 US US09/146,289 patent/US6127373A/en not_active Expired - Fee Related
- 1998-09-03 CA CA002246584A patent/CA2246584C/en not_active Expired - Fee Related
- 1998-09-04 AU AU83106/98A patent/AU732157B2/en not_active Ceased
- 1998-09-04 EP EP98307170A patent/EP0901789B1/de not_active Expired - Lifetime
- 1998-09-04 DE DE69836783T patent/DE69836783T2/de not_active Expired - Fee Related
- 1998-09-04 MY MYPI98004048A patent/MY122052A/en unknown
- 1998-09-04 PT PT98307170T patent/PT901789E/pt unknown
- 1998-09-04 AT AT98307170T patent/ATE350037T1/de not_active IP Right Cessation
- 1998-09-04 NZ NZ331742A patent/NZ331742A/xx unknown
- 1998-09-04 DK DK98307170T patent/DK0901789T3/da active
- 1998-09-04 JP JP10251101A patent/JP3004969B2/ja not_active Expired - Fee Related
- 1998-09-04 ES ES98307170T patent/ES2278405T3/es not_active Expired - Lifetime
- 1998-09-04 ZA ZA9808102A patent/ZA988102B/xx unknown
- 1998-09-05 KR KR1019980036654A patent/KR100621249B1/ko not_active Expired - Fee Related
-
2007
- 2007-03-20 CY CY20071100392T patent/CY1106402T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL125951A (en) | 2003-09-17 |
| DK0901789T3 (da) | 2007-04-10 |
| JP3004969B2 (ja) | 2000-01-31 |
| ES2278405T3 (es) | 2007-08-01 |
| CA2246584C (en) | 2002-09-24 |
| ZA988102B (en) | 2000-03-22 |
| AU732157B2 (en) | 2001-04-12 |
| CA2246584A1 (en) | 1999-03-05 |
| CY1106402T1 (el) | 2011-04-06 |
| DE69836783T2 (de) | 2007-10-31 |
| MY122052A (en) | 2006-03-31 |
| US6127373A (en) | 2000-10-03 |
| EP0901789B1 (de) | 2007-01-03 |
| DE69836783D1 (de) | 2007-02-15 |
| IL125951A0 (en) | 1999-04-11 |
| AU8310698A (en) | 1999-03-18 |
| PT901789E (pt) | 2007-03-30 |
| JPH11180874A (ja) | 1999-07-06 |
| TW448048B (en) | 2001-08-01 |
| KR19990029571A (ko) | 1999-04-26 |
| NZ331742A (en) | 2000-07-28 |
| EP0901789A1 (de) | 1999-03-17 |
| KR100621249B1 (ko) | 2006-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125544T1 (el) | Ενωσεις 1,2,4-οξαδιαζολοβενζοϊκου οξεος και η χρηση τους για μη νοηματικη καταστολη και στη θεραπευτικη αγωγη ασθενειας | |
| DE602004031163D1 (de) | Phenylcarboxamidverbindungen zur Schmerzbehandlung | |
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| PT768086E (pt) | Tratamento de tinido utilizando agentes neuroprotectores | |
| HU9600834D0 (en) | Quinazoline derivatives | |
| DE69736183D1 (de) | Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen | |
| CY1106402T1 (el) | Μεθοδος θepαπειας του συνδρομου tourette | |
| SE0104248D0 (sv) | Method of treatment | |
| DE69431035D1 (de) | 2-Phenyl-3-Azoylbenzothiophene zur Erhöhung der Thrombomodulin Expression | |
| ATE307203T1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
| DE69707372D1 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
| DE69924741D1 (de) | Verwendung einer zusammensetzung zur herstellung eines arzneimittels zur vorbeugung und behandlung von parodontitis | |
| DE69930419D1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
| CA2387394A1 (en) | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder | |
| ATE249830T1 (de) | Die verwendung von r (+)- g(a)-(2,3- dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol zur behandlung von obstruktive schlafapnoe | |
| DE69800906D1 (de) | Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie | |
| DE60206391D1 (de) | Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen | |
| DK0810223T3 (da) | Adamantylsubstituerede oxindoler som farmaceutiske midler | |
| DE69116187D1 (de) | Verwendung eines Dihydropyridins zur Verbesserung der Blutzirkulation des inneren Ohres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0901789 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |